Implications of bedaquiline-resistant tuberculosis
Lancet Infect Dis
.
2022 Feb;22(2):166-167.
doi: 10.1016/S1473-3099(22)00008-1.
Authors
Tom Decroo
1
,
Armand van Deun
2
Affiliations
1
Unit of HIV and TB, Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp 2000, Belgium. Electronic address: tdecroo@itg.be.
2
Leuven, Belgium.
PMID:
35092789
DOI:
10.1016/S1473-3099(22)00008-1
No abstract available
Publication types
Letter
Comment
MeSH terms
Diarylquinolines* / therapeutic use
Humans
Tuberculosis, Multidrug-Resistant* / drug therapy
Substances
Diarylquinolines
bedaquiline